News

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 9 October 2026. It includes information on: New updates Discontinuations Reminders New updates Supply issue: Sildenafil (Vedafil) 50mg tablets There is a supply issue affecting sildenafil (Vedafil) 50mg tablets. Pharmac previously funded a Section 29 alternate brand, Sildenafil (Amarox), in August this year. Stock of this brand is now very low and is expected to be...

Pharmac has decided to fund a new medicine for people in hospital with serious infections and to improve access to medicines for difficult-to-treat bacterial infections and high blood pressure.From 1 November 2026, Pharmac will: Fund ceftolozane with tazobactam for people with serious multidrug-resistant bacterial infections. Widen access to bedaquiline and linezolid for people with non-tuberculous mycobacterial infections. Widen access to captopril oral liquid for people with spinal cord...

This systematic review and network meta-analysis evaluated the benefits and harms of add‑on oral antihistamines for atopic dermatitis (eczema).1 Forty‑seven randomised trials (6230 participants) assessed H1 antihistamines, H2 blockers, mast cell stabilisers, or combinations. With moderate certainty, first‑ and second‑generation H1 antihistamines produced small reductions in eczema severity (mean difference −1.87) and itch (mean difference−0.89), far below the minimal important differences....

Flamazine cream discontinuation The supplier, Smith & Nephew, will stop supplying Flamazine cream (Pharmacode: 2343851) sulfadiazine silver 1% to the New Zealand market. Stock is expected to run out in December 2026/January 2027. Flamazine cream discontinuation Glibenclamide (Daonil) tab 5 mg discontinuation The supplier, Sanofi, is discontinuing Daonil (glibenclamide) tab 5 mg globally. Stock is expected to run out in February 2027. Glibenclamide (Daonil) tab 5 mg discontinuation Updated...

Please see below updates from Pharmac. Supply issue Medsafe approval, Teriparatide Teva Inj 250 mcg per ml, 2.4 ml Brand change Cetirizine hydrochloride oral liquid 1mg/ml 1.Supply Issue update: Medsafe approval, Teriparatide Teva Inj 250 mcg per ml, 2.4 ml An alternate product was funded from August - Teriparatide S29 20 micrograms/80 microlitres, solution for Injection Pre-filled Pen 2.4 ml This UK-branded teriparatide has now received approval from Medsafe. It can be prescribed...

Please see below updates from Pharmac. Supply issue Sildenafil (Vedafil) 50mg tablets. Hydrocortisone acetate (Colifoam) rectal foam 10% Venlafaxine 75 mg capsules (Enlafax XR) Brand change Dimethicone cream 10% pump bottle Discontinuation Daonil (glibenclamide) tab 5 mg Flamazine (silver sulfadiazine cream 1%) 1.Supply Issue: Sildenafil (Vedafil) 50mg tablets There is a supply issue affecting sildenafil (Vedafil) 50mg tablets. Pharmac previously funded a Section 29 alternate brand,...